No public English COA is assigned to this specification yet.
COA · ENGLISH · TR5
The public COA is shown in English and kept in its original laboratory form. Internal self-inspection COAs are private.
Fat loss & metabolism
Tirzepatide
Tirzepatide research material is available in 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg. Select the required specification below. The displayed amount is the price per vial; orders start at 10 vials and increase in multiples of 10.
10Choose a specification1010-vial boxCOAEnglish
Total$32.00$3.20 per vial
Description
Tirzepatide research material is available in 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg. Select the required specification below. The displayed amount is the price per vial; orders start at 10 vials and increase in multiples of 10.
Tirzepatide research material is available in 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg. Select the required specification below. The displayed amount is the price per vial; orders start at 10 vials and increase in multiples of 10.
Supplied strictly as laboratory research material. Record the selected SKU, batch and COA in the research workflow.
Frequently asked questions
About Tirzepatide
How is Tirzepatide priced?+
The displayed price is per vial. The spreadsheet box price has been divided by 10 without changing its total: selecting 10 vials equals one full box.
Which quantities can I select?+
The minimum is 10 vials, and every additional quantity must be a multiple of 10.
How does the COA work?+
When available, the public English COA is linked to the selected specification. Internal self-inspection COAs remain private in the administration area.
What is the intended use?+
This material is supplied strictly for laboratory and research use and is not intended for human or animal use.
RESEARCH & QUALITY DOCUMENTATION
Tirzepatide: research and batch documentation
Content updated · English reference edition
Research overview
Tirzepatide, also described in early research as LY3298176, is studied for activity at both GIP and GLP-1 receptors. Its dual-receptor profile provides a distinct research question from a single GLP-1 agonist. This listing presents research material and its available specifications; it is not a listing for a prescription brand, finished drug or material intended for self-administration.
What the referenced research shows
Receptor assays, animal experiments and an early human study
Coskun and colleagues described LY3298176 in a 2018 discovery-to-clinical-proof-of-concept study. Their work included receptor assays, animal experiments and an early human study. These are separate evidence levels and should be interpreted within their own methods and populations. The reported research does not establish equivalence between an independently supplied research material and the formulation evaluated by the investigators.
The research name LY3298176 helps locate the original literature, but it does not identify a particular commercial batch. Confirm the chemical form and the material-specific identity result. Do not treat a retatrutide/tirzepatide blend as single-compound tirzepatide or transfer analytical results between them.
Questions to ask about this batch
For a tirzepatide enquiry, identify the desired specification and ask for the matching SKU and batch documents. Compare the sample identification on each report with the material being supplied. A public COA supports only the measurements it reports; it does not automatically establish sterility, clinical suitability or equivalence to a prescription product.
Research and documentation FAQ
What does LY3298176 mean in tirzepatide papers?
It is the development identifier used in early tirzepatide research. Searching both terms can help locate the original pharmacology literature.
Is this equivalent to a branded tirzepatide medicine?
No equivalence is claimed. This catalogue listing is research material, not a finished prescription product, and must not be used as a replacement for one.
How should I compare tirzepatide and retatrutide?
Compare the studied receptor targets, material identity and experimental endpoints. Their different receptor profiles do not by themselves establish clinical superiority or interchangeability.
Sources describe the materials and conditions studied by their authors. They are not endorsements of LYSENTA or certificates for the products on this website.
Compare related research materials
Related does not mean interchangeable. Check composition and evidence separately.